Navigation Links
Fenwal, GenesisBPS Enter Agreement for Blood-Specialty Products
Date:1/18/2011

LAKE ZURICH, Ill. and HACKENSACK, N.J., Jan. 18, 2011 /PRNewswire/ -- Fenwal, Inc. of Lake Zurich, Illinois, and GenesisBPS of Hackensack, N.J., announced today they have signed an agreement under which Fenwal will co-market and distribute a range of Genesis-branded products for blood centers, plasma centers and hospitals in the United States and Canada.

The agreement covers products such as Genesis™ blood collection mixers and monitors, RapidSeal II™ tube sealers and automated plasma expressers. Genesis products are designed to help operators improve precision and accuracy in the collection, separation, preparation and storage of blood components.

Fenwal is a global medical technology company focused on improving blood collection, separation, safety and availability. It offers the broadest range of technologies and supplies used in blood collection and transfusion medicine.

"This agreement further expands the Fenwal product offering and enhances the value we bring blood and plasma centers in North America," said Dean Gregory, Fenwal senior vice president of Commercial Operations.

"Fenwal brings high standards for service excellence and extensive knowledge in serving blood and plasma centers," said Adam Grossman, executive vice president of GenesisBPS. "Customers will benefit from the enhanced support and one-stop convenience this partnership creates."

Fenwal will exclusively market and distribute GenesisBPS products to community blood centers and plasma collection centers. GenesisBPS will market and distribute direct to the American Red Cross and U.S. government organizations, and both companies will service hospital accounts.

About Fenwal

Fenwal, Inc. is a global medical technology company focused on improving blood collection, filtration, separation, storage and transfusion to ensure the availability, safety and effectiveness of blood components. Fenwal is unique in the depth of its experience and commitment to transfusion medicine. The company offers the broadest range of products for the automated and manual collection of blood and blood components. Fenwal became an independent company in 2007, but its roots go back to 1949 with the founding of Fenwal Laboratories. Fenwal developed the first flexible, single-use container for blood collection, eliminating complications associated with glass containers and allowing blood to be separated into therapeutic components. Today, the company's products and advanced collection and separation technologies are used to help treat patients on six continents. Fenwal, Inc. is based in Lake Zurich, Illinois. For more information, please visit www.fenwalinc.com.

About GenesisBPS

GenesisBPS provides a complete range of blood specialty products designed to meet the unique and demanding needs of blood collection and processing organizations worldwide. The company focuses on the collection, processing, storage and preparation of blood, blood components and fluids. The Genesis product line includes Genesis™ Blood Collection Mixers and Monitors, Rapid-Seal II™ Tube Sealers, the TCD™ Sterile Tube Welder, PedI-Pak™ pediatric transfusion products, as well as a complete line of ancillary products and supplies. GenesisBPS is based in Hackensack, N.J. For more information, please visit www.genesisbps.com.


'/>"/>
SOURCE Fenwal, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Papastavros Opens New Radiology Centers in Delaware
2. EDC Functionality, Ease of Data Entry, and Access to Data All Factors in University of Virginia Cancer Centers Selection of the OnCore Clinical Research Management System
3. Resolvyx Pharmaceuticals and Celtic Therapeutics Enter Final Agreement in Ophthalmology
4. Key Equipment Finance Enters Long-Term Program Agreement With Hitachi Medical Systems America
5. Saints Medical Center and ZOLL Medical Corporation Enter Collaborative Agreement
6. The Center for Business Intelligence (CBI) Announces Virtual Conference on Imaging for Drug Development
7. Golden Meditech as First Chinese Healthcare Enterprise to Obtain Approval for Taiwan Depositary Receipts Offering
8. New URAC Program to Guide Practices as They Transform Themselves into Patient Centered Health Care Homes Now Available
9. Pfizer Animal Health to Acquire Synbiotics Corporation, Entering Diagnostics Sector
10. Sinovac Receives SFDA Approval to Commence Clinical Trials for Inactivated Enterovirus Type 71 Vaccine
11. InfraReDx Awarded 2010 Tax Incentive From Massachusetts Life Sciences Center
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... March 29, 2017  Experts in the field ... devices like  Soberlink Systems  as a model for ... published in early 2017, concluded that remote blood ... managing patient recovery." The findings of ... Addiction Medicine, detail a range of variables that ...
(Date:3/29/2017)... , March 29, 2017  The leader in accelerated ... Drs. Sam Daher , Manal Ibrahim , ... David Couchat will be the featured microlecture presenters at ... American Association of Orthodontists (AAO) Annual Session, April 21-25, ... the microlectures beginning daily at 11:20 a.m. On the ...
(Date:3/29/2017)... N.J. , March 29, 2017  Glenmark ... results for GSP 301, an investigational fixed-dose combination ... (665 mcg) administered twice-daily as a nasal spray ... rhinitis. These results are from a recently completed ... of GSP 301 combination therapy versus mometasone, olopatadine ...
Breaking Medicine Technology:
(Date:3/29/2017)... ... March 29, 2017 , ... Dr. Angela Cotey, a noted general dentist ... new pediatric patients, with or without a referral. Dr. Cotey knows that interceptive ... outcome and experience. When patients receive early treatment, they may achieve straight teeth with ...
(Date:3/29/2017)... , ... March 29, 2017 , ... Curio Wellness ... to announce the finalization of the company’s executive management team with prominent executives from ... operations is Curio Wellness’ Chief Operating Officer, Ted Dumbauld , who has more ...
(Date:3/29/2017)... ... March 29, 2017 , ... Immunotherapy has emerged as one of ... and is touted to be the next revolution in our fight against this complex ... the form of immune checkpoint inhibitors such as PD-1 and PD-L1 inhibitors. , While ...
(Date:3/29/2017)... ... ... The Wharton School of the University of Pennsylvania is pleased to announce ... million gift to establish the Ken Moelis and Julie Taffet Moelis Advance Access ... MBA for highly-qualified Penn undergraduates whose academic and career interests expand traditional notions of ...
(Date:3/28/2017)... ... March 28, 2017 , ... Tuesday, March 28, 2017, ... public to take the Diabetes Risk Test to find out if they are at ... World Airports will light up the evening sky by programming the LAX pylons the ...
Breaking Medicine News(10 mins):